Related Experiment Videos
Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes
Abstract:
The C3d receptor (CR2) of human B lymphocytes mediates the binding to these cells of immune complexes that have activated the complement system and bear the fragments of C3, iC3b, C3d,g, and C3d. A 145,000 Mr membrane protein previously described as being recognized by the monoclonal antibody HB-5 and shown to be expressed only by B lymphocytes and B lymphoblastoid cell lines, such as Raji, was assessed for its possible identity as CR2. Treatment of Raji cells with HB-5 and goat F(ab')2 anti-mouse IgG (GaM) diminished the capacity of these cells to form rosettes with sheep erythrocyte (E) intermediates bearing 130,000 molecules of iC3b or C3d, whereas treatment with the monoclonal antibody alone had no effect. The capacity of peripheral blood B lymphocytes to bind EC3d was similarly inhibited by the combination of HB-5 and GaM. The possibility that HB-5 may interact with a site on CR2 that is distinct from the ligand binding site permitted the direct analysis of the capacity of the HB-5 antigen to bind to the C3 fragments. Protein A-containing Staphylococcus aureus particles to which HB-5 had been bound were incubated with detergent lysates of Raji cells and B lymphocytes under conditions that had been shown to be associated only with the binding of the 145,000 Mr antigen. These particles bearing HB-5 and antigen derived from either cell type were shown to adhere specifically to EiC3b and EC3d, demonstrating that transfer of the HB-5 antigen from CR2-bearing cells to S. aureus particles led to the acquisition of CR2 function by the particles. The additional findings that the relatively weak capacity of Raji cells to form rosettes with EC3b was inhibited by HB-5 and that the S. aureus particles bearing immunoadsorbed HB-5 antigen bound to EC3b indicated that the C3b-binding function of the CR1-negative Raji cell resides in CR2, rather than in other membrane proteins.
Insights
The C3d receptor (CR2) on B lymphocytes binds complement fragments. Monoclonal antibody HB-5 identifies CR2, confirming its role in immune complex binding.
Area of Science:
- Immunology
- Cell Biology
Background:
- The C3d receptor (CR2) on human B lymphocytes mediates binding of complement-activated immune complexes.
- CR2 recognizes complement fragments like iC3b, C3d,g, and C3d.
Purpose of the Study:
- To identify a 145,000 Mr membrane protein recognized by monoclonal antibody HB-5 as CR2.
- To assess the role of this protein in B lymphocyte binding of complement fragments.
Main Methods:
- Treatment of B lymphocytes and cell lines with monoclonal antibody HB-5 and goat anti-mouse IgG.
- Rosetting assays with sheep erythrocytes bearing complement fragments (iC3b, C3d).
- Immunoadsorption of the HB-5 antigen onto Staphylococcus aureus particles for binding assays.
Main Results:
- HB-5 antibody treatment inhibited B lymphocyte rosette formation with iC3b- and C3d-coated erythrocytes.
- Immunoadsorbed HB-5 antigen specifically bound to iC3b- and C3d-coated erythrocytes.
- HB-5 inhibited binding to C3b-coated erythrocytes, indicating CR2 mediates C3b binding in CR1-negative cells.
Conclusions:
- The 145,000 Mr membrane protein recognized by HB-5 is indeed the C3d receptor (CR2).
- CR2 is responsible for the binding of C3b and C3d fragments to B lymphocytes.
- This study confirms CR2's function in immune complex recognition by B cells.